Dwaipayan Sarathi CHAKRABORTY, Shouvik CHOUDHURY, Sandeep LAHİRY

AVIPTADIL; Class effect of a Synthetic VIP as a treatment option in COVID 19 patients with severe respiratory failure

Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited. Vasoactive peptide (VIP) has diversified physiological action with specific features of lung protection-related activities. VIP inhibits SARS COV-2 gene replication in human monocytes and viral replication in Calu -3 cells thus further reducing the generation of proinflammatory mediators Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials Initial binding of Aviptadil with nsp10 & nsp 16 which may inhibit the 2 -O-MTase activity of the SARS-CoV nsp10/16 complex Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. Interim analysis results of this drug use in respiratory failures caused by SARS COV-2 has evolved a new hope in regards to safety and efficacy. Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.

PDF

___

1. Chacko J, Unais M. Pharmacologic treatment of COVID-19: Evidencebased update. Indian J Respir Care. 2021;10,Suppl S1:34-8
2. Heustess AM, Allard MA, Thompson DK, et al. Clinical management of COVID-19: A Review of pharmacological treatment options. Pharmaceuticals. 2021;14:520.
3. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature.1970;225:863-4.
4. Li L, Hua S, Yue S, et al. Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c- Fos pathway. Peptides. 2010;31:2016-51.
5. Mossel EC, Wang J, Jeffers S, et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008;372:127-35.
6. Tang H, Welton A, Ganea D. Neuropeptide regulation of cytokine expression: Effects of VIP and RO 25-1553. J Interferon Cytokine Res. 1995;15:993-1003.
7. Voice JK, Grinninger C, Kong Y, et al. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol. 2003;170:308-14.
8. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med. 2007;13:241-51.
9. Delgado, Mario Martínez, Carmen Pozo, David et al. Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6. J Immunol. 1999;162:1200-5.
10. Berisha HI, Bratut M, Bangale Y, et al. New evidence for transmitter role of VIP in the airways: Impaired relaxation by a catalytic antibody. PulmPharmacolTher. 2002;15:121-7.
11. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activationinduced cell death is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors J Immunol. 2005;176:97–110.
12. Said SI. Vasoactive intestinal peptide in the lung. Ann N Y Acad Sci. 1988;527:450-64.
13. Hasaneen NA, Foda HD, Said SI. Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice. Chest. 2003;124:1067-72.
14. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians. 1984;97:304-10.
15. Nagahiro I, Yano M, Boasquevisque CH, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation J. Heart Lungn Transplant. 1998;17:617-21.
16. Virgolini, A Kurtaran, M Raderer. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995;36:1732–9.
17. Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia. 2013;17:12-6.
18. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995 36:1732-9.
19. H Pakbaz, H Berisha, H Sharaf, et al. VIP enhances and nitric oxide synthaseinhibitor reduces survival of rat lungs perfused ex vivo. Ann N Y Acad Sci. 1994;723:426-8.
20. Li L, She H, Yue SJ, et al. Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids. RegulPept. 2007 3;140:117-24.
21. Delgado M, Munoz-Elias EJ, Kan Y, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factorkB and cAMP response element-binding protein/c-Jun J. Biol. Chem. 1998;273:31427–36.
22. Mason R J. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55:2000607.
23. Onoue S, Ohmori Y, Endo K, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur. J. Biochem. 2004;271:1757-67.
24. Temerozo, Jairo & Sacramento, Carolina & Fintelman-Rodrigues, Natalia & Pao, et al. The neuropeptides VIP and PACAP inhibit SARSCoV- 2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.
25. Li L, Luo ZQ, Zhou, et al. Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. Acta Pharmacol Sin. 2004;25:1652-8.
26. Li L, Hua S, Yue S, et al. Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c- Fos pathway. Peptides. 2010;31:2016-51.
27. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Vasoactive intestinal peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia. 2013;17:12-6.
28. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL- 6. J Immunol. 1999;162:1200-5.
29. Delgado M, Munoz-Elias EJ, Kan Y, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun J Biol Chem. 1998;273:31427-36.
30. Hashimoto S, Kobayashi A, Kooguchi K, et. al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in spetic acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000,161:237-43.
31. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activationinduced cell death is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol. 2006;176:97-110.
32. Jonathan C. Javitt, MD, MPH. Perspective: The Potential Role of Vasoactive Intestinal Peptide in treating COVID-19. Authorea. May 13, 2020.
33. Raveendran AV, dhuhli AL, Khalid Salim, Kumar HG. Role of Aviptadil in COVID-19. BMH Medical J. 2021;8:77-83.
34. Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32:1289– 94.
35. Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J RespirCrit Care Med. 2010 15;182:540-8.
36. Youssef, Jihad G and Said, Sami and Youssef, George and Javitt, Matthew J. and Javitt, Jonathan, Treatment of Sepsis-related Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide Available at SSRN: https:// ssrn.com/abstract=3662952 access date July 29, 2020.
37. Chen G, Wu D, Guo, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9. 38. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathogens. 2020;16:e1008536.
39. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front. Immunol. 2020;16;11:1446.
40. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune Host Microbe. 2020;27:992-1000. 41. Bouvet M, Debarnot C, Imbert I, et al. In vitro reconstitution of SARScoronavirus mRNA cap methylation. PLoSPathog. 2010;6:e1000863.
42. Bollati M, Milani M, Mastrangelo E, et al. Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: implications for RNAcapping mechanisms in Flavivirus. J Mol Biol. 2009;385:140-52.
43. Sultan F. Alnomasy, Bader S. Alotaibi, Ziyad M. Aldosari et al. Inhibitory effects of aviptadil on the SARS-CoV-2 nsp10/ nsp16 protein complex. Research Square. 2021
44. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55:2000607.
45. Youssef JG, Zahiruddin F, Al-Saadi M, et al. Brief report: rapid clinical recovery from critical COVID-19 with respiratory failure in a lung transplant patient treated with intravenous vasoactive intestinal peptide. Preprints 2020;2020070178.
46. Youssef JG, Lee R, Javitt J, et al. Intravenous Aviptadil Is Associated with Increased Recovery and Survival in Patients with COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. SSRN. Critical Care Exploration. 2021;4:e0607.